| Literature DB >> 36079075 |
Redwan Jabbar1, Bartosz Szmyd1, Jakub Jankowski1, Weronika Lusa1,2, Agnieszka Pawełczyk1, Grzegorz Wysiadecki3, R Shane Tubbs4,5,6,7,8, Joe Iwanaga4,6, Maciej Radek1.
Abstract
Intramedullary spinal cord abscess (ISCA) is a rare clinical pathology of the central nervous system that usually accompanies other underlying comorbidities. Traditionally it has been associated with significant mortality and neurological morbidities because it is often difficult to diagnose promptly, owing to its nonspecific clinical and neuroimaging features. The mortality rate and the outcome of these infections have been improved by the introduction into clinical practice of antibiotics, advanced neuroimaging modalities, and immediate surgery. We report the case of a 65-year-old male patient who presented with a progressive spastic gait and lumbar pain, predominantly in the left leg. An MRI image revealed an expansile intramedullary cystic mass in the thoracic spinal cord, which was initially diagnosed as a spinal tumor. He underwent laminectomy and myelotomy, and eventually the pus was drained from the abscess. The follow-up MRI showed improvement, but the patient's paraplegia persisted. In light of his persistent hypoesthesia and paraplegic gait with developing neuropathic pain, he was readmitted, and an MRI of his lumbar spine revealed multilevel degenerative disease and tethered spinal cord syndrome with compression of the medulla at the L2-L3 level. The patient underwent central flavectomy with bilateral foraminotomy at the L2-L3 level, and the medulla was decompressed. Postoperatively, his neurological symptoms were significantly improved, and he was discharged from hospital on the third day after admission. In support of our case, we systematically reviewed the recent literature and analyzed cases published between 1949 and May 2022, including clinical features, mechanisms of infection, predisposing factors, radiological investigations, microbial etiologies, therapies and their duration, follow-ups, and outcomes. Initial clinical presentation can be misleading, and the diagnosis can be challenging, because this condition is rare and coexists with other spinal diseases. Hence, a high index of suspicion for making an accurate diagnosis and timely intervention is required to preclude mortality and unfavorable outcomes. Our case is a clear example thereof. Long-term follow-up is also essential to monitor for abscess recurrences.Entities:
Keywords: abscess; intramedullary spinal cord abscess (ISCA); laminectomy; myelotomy; spinal cord
Year: 2022 PMID: 36079075 PMCID: PMC9457049 DOI: 10.3390/jcm11175148
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.964
Figure 1Magnetic resonance imaging (MRI) showing the sagittal scans: (A) T2-weighted image and (B) T1-weighted images of an expansile intramedullary solid-cystic lesion measuring 16 mm × 11 mm × 10 mm, without contrast enhancement, at the T4 level, with segmental widening of the spinal cord above and below the lesion. The early follow-up MRI shows no pathological mass and postoperative changes on both (C) T1-weighted and (D) T2-weighted images. The MRI performed 6 months after surgery revealed complete abscess excision in (E) T2-weighted and (F) T1-weighted sequences.
Figure 2Intraoperative view of lesion showing yellowish pus after myelotomy at T4 level.
Figure 3Lumbar multilevel spinal degenerative disease on MRT2-weighted images: (A,B) sagittal and (C) axial view at L2–L3 level; severe stenosis with compression of the conus medullaris.
Figure 4The flow-chart of publications included process.
Figure 5The typical clinical features of intramedullary spinal cord abscesses. Legend: ISCA—intramedullary spinal cord abscess.
Recovery group—summary of the clinical data, patient demographics, clinical manifestations, duration, microbiology, interventions and therapies, and outcomes of contemporary case reports on intramedullary spinal cord abscess (ISCA) in the current literature: systemic review of literature (1949–2022).
| No. | Age | Sex | Onset | Location | Infl. | Symptoms | Symptoms to Treatment | Neurosurgical Management | Antibiotics | Pathogen | MOA | Follow-Up | Outcome | Ref. | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Name | Duration | Name | Duration | |||||||||||||
| 1 | 64 | M | Acute | N/D | + | ND (M + S) | N/D | N/D | N/D | Flucytosine Amphotericin B IV | 10 d |
| Cryptogenic | 1 y | Recovery | [ |
| 2 | 27 | M | Acute | C5 | + | ND (M) | ND | N/D | Stereotactic needle aspiration | Ampicillin IV, Metronidazole IV, Trimethoprim-Sulfamethoxazole IV, Ampicillin PO | 3 w |
| Cryptogenic (Intrapulmonary AVF causing a right-to-left shunt) | N/D | Recovery | [ |
| 3 | 80 | F | Acute | T8 | + | ND (M) | 3 d | 3 d | N/D | Ceftriaxone, Dexamethasone Metronidazole | 6 w |
| Cryptogenic | 11 w | Recovery | [ |
| 4 | 57 | M | Acute | C6-T1 | + | ND (M + S) | Sd | N/D | Myelotomy, DR | Vancomycin | 6 w |
| Cryptogenic | N/D | Recovery | [ |
| 5 | 53 | M | Acute | CM | + | ND (M + S) | 5 d | Urgent | N/D | N/D | N/D |
| Cryptogenic | 4 m | Recovery | [ |
| 6 | 42 | M | Acute | C7 | + | ND (M) | 5 d | N/D | Laminectomy, DR | Linezolid | 2 w |
| Hematogenous (IE) | N/D | Recovery | [ |
| 7 | 21 | M | Subacute | T12-L2 | + | ND (M + S) | N/D | N/D | Myelotomy, EEC, IAC (Penicillin & Gentamicin | Penicillin IV, Flucloxacillin IV, Gentamicin IV | N/D |
| Contiguous (Epidermoid tumor) | 4 m | Recovery | [ |
| 8 | 52 | M | Subacute | L1 | N/D | ND (M + S) | N/D | N/D | DR | Trimethoprim Sulfamethoxazole Imipenem-Cilastin (After Antibiogram: Trimethoprim-Sulfamethoxazole Minocycline | 1 Y |
| Cryptogenic | 16 m | Recovery | [ |
| 9 | 25 | F | Subacute | C5-C6 | + | ND (M + S) | 3 w | N/D | Myelotomy, DR | Isoniazid, Rifampin, Myambutol Pyrazinamide | 7 w |
| Hematogenous (Brown Sequard syndrome; Tuberculosis & SLE) | 40 d (posthospital adm) | Recovery | [ |
| 10 | 56 | M | Subacute | C3-C4 | + | ND (M + S) | S d | N/D | N/D | Amikacin, Ceftazidime, Ciprofloxacin | 3 m |
| Hematogenous | 34 m | Recovery | [ |
| 11 | 70 | M | Subacute | C4-C5 | + | ND (M + S) | 3 | N/D | Yes (N/S) | Ceftriaxone, Gentamicin, Amoxicillin PO | 6 w, 2 w, 3 m |
| Hematogenous (IE, radiotherapy) | 3 m | Recovery | [ |
| 12 | 59 | M | Subacute | C7-T1 | + | ND (M + S) | 1 w | 9 d | N/D | Ampicillin, Ceftriaxone, Cefpirome, Ampicillin PO | 2 m |
| Cryptogenic (Chronic sinusitis) | 2 m | Recovery | [ |
| 13 | 51 | M | Subacute | T2-MO | + | ND (M + S) | 1 w | Urgent | N/D | Meropenem, Vancomycin, Steroid-Pulse Therapy & Immunoglobulin IV | 4 w, 3 d, 3 d |
| Hematogenous (Dental procedure) | 3 m | Recovery | [ |
| 14 | 22 | M | Chronic | T12-L1 | + | ND (M + S) | >2 m | Urgent | Myelotomy, DU, DR | Yes (N.S.) | N/D |
| Contiguous (spinal anesthesia) | 40 d | Recovery | [ |
| 15 | 82 | M | Chronic | T6-T7 | + | ND (M + S) | 4 m | N/D | N/D | Steroids, Gentamicin, Ciprofloxacin IV, Ciprofloxacin IM | 10 w, 4 w, 2 m |
| Hematogenous (UTI—diabetes) | 3 m | Recovery | [ |
| 16 | 28 | M | Chronic | T11 | + | ND (M + S) | 6 m | N/D | Y (N/S) | N/D | N/D |
| Cryptogenic (Infection) | N/D | Recovery | [ |
| 17 | 67 | M | Chronic | T10-T11 | + | ND (M + S) | 1 Y | 1 Y | SDAVF embolization | Dexamethasone Meropenem IV, Moxifloxacin PO (Alone from day 71) | 4 d, 112 d |
| Hematogenous (SDAVF) | N/D | Recovery | [ |
| 18 | 44 | M | Chronic | T3 | + | ND (M + S) | 3 m | N/D | N/D | Amphotericin B Itraconazole | N/D, |
| Hematogenous (CNS histoplasmosis) | 1 m | Recovery | [ |
| 19 | 52 | M | N/D | C4-C5 | + | ND (M + S) | N/D | N/D | DR | Oxacillin | N/D |
| Direct inoculation (penetrating trauma) Wooden Foreign Body (WBS) | 8 w | Recovery | [ |
| 20 | 55 | M | N/D | Cervical | + | ND (M) | Sw | Urgent | Laminectomy | N/D—(Steroids, Amphotericin) | N/D |
| Hematogenous (Disseminated coccidioidomycosis) | 2 m | Recovery | [ |
Legend: sex: F—female, M—male; location: C—cervical, T—thoracic, L—lumbar, S—sacral; infl.—inflammation; symptoms: M—motor, ND—neurological deficits, S—sensory; duration: D—day, M—months, Y—years, SW—several weeks; others: CM—conus medullaris, DR—drainage, DU—durotomy, EST—excision sinus tract, EAC—excision of abscess cavity, EEC—excision of epidermoid cyst, IAC—irrigation of abscess cavity, N/D—no data, N/S—not specified.
Radiological features (myelography, CT, MRI) of intramedullary spinal cord abscess (ISCA).
| Myelography (n = 8) |
|---|
| Spinal cord widening and swelling |
| CSF flow obstruction |
| Tethering of conus |
|
|
| Segmental widening and swelling of cord |
| Complete or partial obstruction of CSF flow |
|
|
| Segmental widening and swelling of spinal cord |
| Ring-enhancing margin (abscess) |
| Cystic lesion with ring enhancement |
| CSF flow obstruction |
Residual group—summary of the clinical data, patient demographics, clinical manifestations, duration, microbiology, interventions and therapies, and outcomes of contemporary case reports on intramedullary spinal cord abscess (ISCA) in the current literature: systemic review of literature (1949–2022).
| No. | Age | Sex | Onset | Location | Infl. | Symptoms | Symptoms to Treatment | Neurosurgical Management | Antibiotics | Pathogen | MOA | Follow-Up | Outcome | Ref. | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Name | Duration | Name | Duration | |||||||||||||
| 1 | 72 | M | Acute | C6-T2 | + | ND (M + S) | 5 d | Urgent | Myelotomy, EAC | Penicillin | 6 w |
| Cryptogenic (spinal cord ependymoma) | 6 w | Survived; residual ND | [ |
| 2 | 59 | M | Acute | C3-C7 | + | ND (M + S) | 6 d | N/D | Myelotomy, DR | Cefepime IV | 6 w |
| Cryptogenic (Plausible infection & long immobility) | N/D | Survived; residual ND | [ |
| 3 | 44 | F | Acute | C2-C5 | N/D | ND (M + S) | 4 d | 5 d | Myelotomy, DU | Meropenem, Vancomycin, Ceftriaxone | N/D |
| Cryptogenic | 1 m | Survived; residual ND | [ |
| 4 | 35 | M | Acute | C2-C5 | + | ND (M + S) | 2 d | 2 d | Myelotomy, DR | Azithromycin, Ceftriaxone, Vancomycin, | 1 m |
| Hematogenous (Sickle cell disease) | 12 d | Survived; residual ND | [ |
| 5 | 47 | M | Subacute | T11 | N/D | ND (M + S) | 3 w | Urgent | Myelotomy, DU, DR, IAC | N/D | N/D |
| Contiguous (Intrathecal morphine pump) | 20 m | Survived; residual ND | [ |
| 6 | 82 | F | Subacute | T12-L1 | + | ND (M + S) | 3 w | N/D | Laminectomy | Meropenem IV, Trimethoprim–Sulfamethoxazole IV | 6 w |
| Cryptogenic | 7 w | Survived; residual ND | [ |
| 7 | 77 | M | Subacute | L5-S1 | + | ND (M) | 10 d | 11 d | Laminectomy, drainage | Oxacillin, Clindamycin | N/D |
| Cryptogenic (Possibly arthritis) | 3 m | Survived; residual ND | [ |
| 8 | 42 | F | Chronic | T12 | + | ND (M + S) | 3.5 m | 2 d | Laminectomy | Sulphonamides, N.S. | 4 m |
| Hematogenous spread (Urinary tract infection) | 9 m | Survived; residual ND | [ |
| 9 | 40 | F | Chronic | T12-L2 | + | ND (M + S) | 6 m | N/D | Myelotomy, DU, DR | Streptomycin, Doxycycline, Rifampicin | 2 m |
| Hematogenous (Consumption: unpasteurized goat’s milk | 2 y | Survived; residual ND | [ |
| 10 | 65 | M | Chronic | T11-CA | + | ND (M + S) | 2 m | N/D | N/D | Linezolid | 2 w |
| Hematogenous (IE) | 1 y | Survived; residual ND | [ |
| 11 | 66 | M | N/D | T5-T6 | + | ND (M + S) | N/D | N/D | N/D | Metronidazole Clindamycin | 6 w |
| Hematogenous (?) (spondylodiscitis) | 6 w | Survived; residual ND | [ |
| 12 | 45 | F | Acute | C2-C6 | + | ND (M + S) | 2 w | N/D | N/D | Cefuroxime | 6 w |
| Hematogenous (Sepsis, UTI) | N/D | Survived; residual ND | [ |
Legend: sex: F—female, M—male; location: C—cervical, T—thoracic, L—lumbar, S—sacral; infl.—inflammation; symptoms: M—motor, ND—neurological deficits, S—sensory; duration: D—day, W—weeks, M—months, Y—years, SW—several weeks; others: CM—conus medullaris, DR—drainage, DU—durotomy, EAC—excision of abscess cavity, IAC—irrigation of abscess cavity, N/D—no data.
Persistent group—summary of the clinical data, patient demographics, clinical manifestations, duration, microbiology, interventions and therapies, and outcomes of contemporary case reports on intramedullary spinal cord abscess (ISCA) in the current literature: systemic review of literature (1949–2022).
| No. | Age | Sex | Onset | Location | Infl. | Symptoms | Symptoms to Treatment | Neurosurgical Management | Antibiotics | Pathogen | MOA | Follow-Up | Outcome | Ref. | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Name | Duration | Name | Duration | |||||||||||||
| 1 | 71 | M | Acute | C3-C6 | + | ND (M + S) | 5 d | N/D | IAC | Penicillin IV Chloramphenicol IV, Penicillin PO | 5 w |
| Cryptogenic | 3 m | Survived; persistent ND | [ |
| 2 | 50 | M | Acute | C4-C7 | + | ND (M + S) | N/D | N/D | Myelotomy | Cefoperazone IV Ciprofloxacin IV | 8 w |
| Cryptogenic (IV drug use) | 8 w | Survived; persistent ND | [ |
| 3 | 72 | M | Acute | C6-T2 | + | ND (M + S) | 5 d | Urgent | Myelotomy, EAC | Penicillin | 6 w |
| Cryptogenic (spinal cord ependymoma) | 6 w | Survived; residual ND | [ |
| 4 | 73 | M | Acute | T10-T11 & CM | + | ND (M) | N/D | 3 d | N/D | Ampicillin IV | 3 m |
| Hematogenous spread (alcoholism, sepsis) | 9 m | Survived; persistent ND | [ |
| 5 | 55 | M | Acute | T3-T7 | ND (M) | 2 d | 3 d | ND | Ampicillin IV | 24 d |
| Hematogenous spread (alcoholism, sepsis) | 18 m | Survived; persistent ND | [ | |
| 6 | 37 | M | Acute | T8-T9 | + | ND (M + S) | 6 w | Urgent | Myelotomy | Antituberculosis Treatment PO & IV | N/D |
| Cryptogenic | 2 m | Survived; persistent ND | [ |
| 7 | 23 | F | Acute | T11-T12 | + | ND (M) | N/D | 3 w | Laminectomy, NA | Isoniazid, Rifampicin, Pyrazinamide | N/D |
| Cryptogenic | N/D | Survived; persistent ND | [ |
| 8 | 22 | F | Acute | Holocord | + | ND (M + S) | N/D | N/D | Myelotomy, radical debulking | N/D | N/D |
| Cryptogenic | 1 y | Survived; persistent ND | [ |
| 9 | 47 | F | Acute | C7-T11 | N/D | ND (M + S) | 1 w | Urgent | Myelotomy | Yes (N/S) | N/D |
| Hematogenous (Oral infection) | N/D | Survived; Persistent, ND | [ |
| 10 | 27 | M | Acute | C4-C5 | + | ND (M + S) | 1 w | N/D | Myelotomy, DR | Yes (N/S) | N/D |
| Hematogenous (CKD, systemic infection) | N/D | Survived; Persistent, ND | [ |
| 11 | 61 | M | Acute | T10-T11 | + | ND (M + S) | 1 m | N/D | Myelotomy, IE | N/D | 1 m |
| Hematogenous (Systemic infection—diabetes) | 35 d | Survived; Persistent, ND | [ |
| 12 | 72 | M | Acute | C5, T6-T7 | + | ND (M + S) | 1 w | Urgent | Myelotomy, DR, DU | Ceftriaxone, Vancomycin, Ampicillin, Metronidazole, | 6 w |
| Cryptogenic | 4 w | Survived, persistent ND | [ |
| 13 | 42 | M | Subacute | C4-C5 | + | ND (M) | 15 d | 2 d | Myelotomy | Penicillin IM, Chloramphenicol | 4 w | Contiguous spread (Stab wound) | 8 m | Survived, persistent ND | [ | |
| 14 | 20 | F | Subacute | L4-L5 | + | ND (M + S) | N/D | N/D | EST | Gentamicin IV, Flucloxacillin IV, Metronidazole IV | N/D |
| Contiguous (dermal sinus tract, previous meningitis; prior resection of lumbar meningocele) | 5 m | Survived; persistent ND | [ |
| 15 | 26 | M | Subacute | L1-L4 | + | ND (M + S) | N/D | N/D | Myelotomy, IAC | Penicillin, Chloramphenicol, Metronidazole | 5 m |
| Cryptogenic (spina bifida occulta; prior excision of intradural lipoma) | 3.5 y | Survived; persistent ND | [ |
| 16 | 42 | M | Subacute | C1-T3 | + | ND (M) | 3 w | Urgent | Myelotomy, DR | Bristopen Peflacine | N/D |
| Cryptogenic (IV drug use) | 5 m | Survived; persistent ND | [ |
| 17 | 33 | M | Subacute | T12-L3 | + | ND (M + S) | 3 m | N/D | Biopsy | Pipellacillin-Sodium Erythromycin | 6 m |
| Cryptogenic | N/D | Survived; persistent ND | [ |
| 18 | 28 | M | Subacute | Cervical-MO | + | ND (M + S) | 3 w | Urgent | Laminectomy, DR | Broad-Spectrum Antimicrobials | N/D |
| Contiguous | N/D | Survived; persistent ND | [ |
| 19 | 78 | M | Subacute | T9 | + | ND (M + S) | 14 d | 10 | Myelotomy, DU, DR | Ampicillin, Cefotaxime | N/D |
| Cryptogenic | 2 m | Persistent, ND | [ |
| 20 | 65 | F | Subacute | CMJ-T1 | + | ND (M + S) | 2 w | Urgent | Myelotomy, DR, DU | Ceftriaxone, Vancomycin, Metronidazole, Penicillin G, Meropenem, Linezolid | 6 w |
| Cryptogenic | 16 m | Survived, persistent ND | [ |
| 21 | 69 | M | Subacute | C2-C7 | + | ND (M + S) | N/D | N/D | N/D | Ampicillin IV Gentamicin | 12 w, 14 w |
| Cryptogenic (Spinal stenosis with spinal cord stenosis) | 2 m | Survived; persistent ND | [ |
| 21 | 61 | M | Chronic | T9 | N/D | ND (M + S) | 4 m | 1 d | Myelotomy, EAC | Yes (Not Specified) | N/D |
| Cryptogenic | 1 y | Survived; persistent ND | [ |
| 22 | 55 | F | Chronic | T1-T2 | + | ND (M + S) | N/D | N/D | Myelotomy, IAC | Vancomycin IV, Ceftazidime IV | 2/6 w |
| Cryptogenic | N/D | Survived; persistent ND | [ |
| 23 | 68 | M | Chronic | T1-T2 | + | ND (M + S) | N/S | N/S | N/D | Cefotaxime IV | 6 w |
| Cryptogenic | 3 y | Survived; persistent ND | [ |
| 24 | 19 | M | Chronic | CM | N/D | ND (M + S) | 3 m | N/D | Myelotomy | N/D | N/D |
| Cryptogenic | 1 y | Persistent, ND | [ |
| 25 | 72 | M | Chronic | Thoracic-Lumbar | + | ND (M + S) | 5 d | N/D | Laminectomy, DR | Tazobactam/Piperacillin (Hospitalization Onset, No More Info About Drugs) | ~1 Y |
| Hematogenous (Diabetes mellitus, recurrent liver abscess) | ~1 y | Persistent ND | [ |
| 26 | 32 | M | N/D | C3-C6 | + | ND (M + S) | N/D | 14 d | Myelotomy | Ampicillin IV, Chloramphenicol IV Ampicillin PO | 4 w |
| Hematogenous spread (Alcoholism, sepsis) | 18 m | Survived; persistent ND | [ |
| 27 | 50 | M | N/D | C5-C7 | + | ND (M) | N/D | N/D | Laminectomy, myelotomy, DR | Gentamicin, Fucidin Pefloxacin | N/D |
| Contagious (Epidural abscess induced septic thrombophlebitis of the veins of the spinal cord—leading to venous infarction & abscess of the spinal cord) | N/D | Survived; persistent ND | [ |
| 28 | 30 | F | Subacute | T3-T7 | _- | ND (M + S) | 1 m | N/D | Laminectomy, myelotomy, EAC | ATT therapy | >6 m |
| Hematogenous | 7 m | Survived, persistent ND | [ |
Legend: sex: F—female, M—male; location: C—cervical, T—thoracic, L—lumbar, S—sacral; infl.—inflammation; symptoms: M—motor, ND—neurological deficits, S—sensory; duration: D—day, M—months, Y—years, SW—several weeks; others: CM—conus medullaris, CMJ—craniocervical junction, DR—drainage, DU—durotomy, EST—excision sinus tract, EAC—excision of abscess cavity, IAC—irrigation of abscess cavity, N/D—no data, N/S—not specified.
Death group—summary of the clinical data, patient demographics, clinical manifestations, duration, microbiology, interventions and therapies, and outcomes of contemporary case reports on intramedullary spinal cord abscess (ISCA) in the current literature: systemic review of literature (1949–2022).
| No. | Age | Sex | Onset | Location | Infl. | Symptoms | Symptoms to Treatment | Neurosurgical Management | Antibiotics | Pathogen | MOA | Follow-Up | Outcome | Ref. | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Name | Duration | Name | Duration | |||||||||||||
| 1 | 76 | M | Acute | T3-T12 | + | ND (M + S) | N/D | N/D | N/D | Yes (Not Specified) | 3 w |
| Hematogenous spread (Septic embolus, pyelonephritis) | 3 w | Died | [ |
| 2 | 51 | M | Acute | Cervical | + | ND (M + S) | N/D | N/D | N/D | N/D | N/D |
| Hematogenous spread (Alcoholism, bronchopneumonia) | N/D | Died | [ |
| 3 | 59 | M | Acute | C4-C6 | + | ND (M + S) | N/D | N/D | Myelotomy | Chloramphenicol IV Ceftazidime IV Metronidazole | 31 d |
| Hematogenous spread (bronchiectasis) | 31 d | Died | [ |
| 4 | 59 | M | Subacute | C3-T1 | + | ND (M + S) | 2 w | Urgent | Laminectomy, DR | Amikacin, Ceftriaxone | 12 d |
| Hematogenous spread (Cerebral abscess, diabetes) | N/D | Died | [ |
| 5 | 79 | M | Acute | C3-C4 | + | ND (M + S) | S d | N/D | N/D | IV Trimethoprim-Sulfamethoxazole, Dexamethasone | 10 |
| Hematogenous spread | N/D | Died | [ |
| 6 | 45 | F | Acute | C2-C6 | + | ND (M + S) | 2 w | N/D | N/D | Cefuroxime | 6 w |
| Hematogenous spread (Sepsis, UTI) | N/D | Died | [ |
| 7 | 19 | M | N/D | T12-L1 | N/D | ND (M + S) | Sw | N/D | Laminectomy, USG—guided aspiration | Voriconazole | N/D |
| Contagious (Vertebral discitis, osteomyelitis) | N/D | Died | [ |
| 8 | 69 | M | Subacute | T7-CM | + | ND (M + S) | 17 d | N/D | N/D | Ceftriaxone, Metronidazole—On the 3rd day of admission. | 1 w |
| Cryptogenic (suspicion of hematogenous, (Diabetes mellitus) | N/D | Died | [ |
| 9 | 50 | M | C2-C6 | ND (S) | myelotomy | N/D | N/D |
| Hematogenous spread (sepsis) | N/D | Died | [ | ||||
| 10 | 44 | F | Chronic | T10-T11 | + | ND (M + S) | >1 Y | N/D | Laminectomy, DR | N/D | N/D |
| Hematogenous spread (History of CNS fungal infection and neurotuberculosis) | N/D | N/D | [ |
Legend: sex: F—female, M—male; location: C—cervical, T—thoracic, L—lumbar, S—sacral; infl.—inflammation; Symptoms: M—motor, ND—neurological deficits, S—sensory; duration: D—day, M—months, Y—years, SW—several weeks; others: CM—conus medullaris, DR—drainage, EEC—excision of epidermoid cyst, IAC—irrigation of abscess cavity, N/D—no data, N/S—not specified.
Figure 6The typical localization of spinal cord abscess in 61 patients with intramedullary spinal cord abscess.